Company that raised price of AIDS drug Daraprim by 5500% ‘under investigation’

Oct 14, 2015
Health, Safety & Testing
0 0

The New York Attorney General has launched an investigation into a company that raised the price of AIDS drug Daraprim by 5500%.

Martin Shkreli, the 32-year-old founder and chief executive of Turing Pharmaceuticals, came under fire last month after buying the rights to 62-year-old drug Daraprim.

The New York Attorney General has launched an investigation into a company that raised the price of AIDS drug Daraprim by 5500%.

The drug costs less than $1 per tablet to make, and is used to treat conditions including AIDS-related toxoplasmosis.

However, Shkreli last month attempted to dramatically increaser the price of the drug from $13.50 per tablet to $750 – an increase of 5500%.

He later publicly pledged “to lower the price of Daraprim to a point that is more affordable” – though the drug has since remained at the high price point.

New York’s attorney general this week launched a probe into Turing Pharmaceuticals over the move, which may have violated the law.

Keep reading

0 0 vote
Article Rating
Spread the love
Subscribe
Notify of
guest

This site uses Akismet to reduce spam. Learn how your comment data is processed.

0 Comments
Inline Feedbacks
View all comments
TrafficHolder.com - Buy & Sell Adult Traffic
0
Would love your thoughts, please comment.x
()
x